Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation

Diabetes/metabolism Research and Reviews
Evertine J AbbinkCees J Tack

Abstract

The more rapid onset of action and the shorter half-life of repaglinide may reduce the post-load glucose excursion and limit sustained insulin secretion compared to sulphonylurea (SU) derivatives. We studied 12 patients with type 2 diabetes (age 62 +/- 2 years, BMI 28.3 +/- 1.3 kg m(-2), HbA1c 6.7 +/- 0.2%) on SU monotherapy at submaximal dose. Patients were treated for 3 weeks with repaglinide or glibenclamide in a randomized, crossover trial. At the end of each treatment period, patients underwent a 60-min hyperglycaemic clamp (glucose 12 mmol L(-1)) followed by 4-h observation (60-300 min) with frequent blood sampling for determination of glucose, insulin, proinsulin and C-peptide levels. Before the clamp (5 min for repaglinide, 30 min for glibenclamide), patients ingested their usual morning drug dose. After the end of the hyperglycaemic clamp, mean plasma glucose fell to a level of 5 mmol L(-1) after approximately 150 min with repaglinide, and after approximately 190 min with glibenclamide. While initially quite similar, in the period from 240 to 300 min, insulin, proinsulin and C-peptide levels were lower during repaglinide treatment (insulin 133 +/- 20 vs 153 +/- 25 pmol L(-1) (P < 0.05), proinsulin 14 +/- 3 vs 19 +/- 4 ...Continue Reading

References

May 11, 1992·Diabetes Care·R M CohenR S Clements
Jun 1, 1992·Diabetes Care·L C Groop
Jul 1, 1997·Diabetic Medicine : a Journal of the British Diabetic Association·P S van der WalR J Heine
May 19, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·D R MatthewsR C Turner
Apr 16, 1999·Endocrine Reviews·L Aguilar-Bryan, J Bryan
Aug 24, 1999·Annals of Internal Medicine·R A DeFronzo
Apr 20, 2001·Diabetes Research and Clinical Practice·P S van der Wal, R J Heine
Jul 27, 2001·Diabetic Medicine : a Journal of the British Diabetic Association·S MadsbadUNKNOWN Scandinavian Repaglinide Group
May 8, 2002·Diabetes/metabolism Research and Reviews·Evertine J AbbinkPaul Smits

❮ Previous
Next ❯

Citations

Oct 10, 2014·Diabetologia·Axel RiefflinJonathan C Levy
Oct 24, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Odd Erik Johansen, Kåre I Birkeland
Aug 23, 2005·Diabetes/metabolism Research and Reviews
Dec 31, 2019·Current Topics in Medicinal Chemistry·Wei LvWencong Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.